EMA Authorised: Voncento (human coagulation factor VIII;human von willebrand factor) — CSL Behring GmbH

View source ↗

Summary

The EMA authorised Voncento, a Factor VIII/von Willebrand factor concentrate by CSL Behring, for treatment of Hemophilia A and von Willebrand disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia
• Von Willebrand Disease

Drugs mentioned

• Voncento (Factor VIII/von Willebrand factor concentrate)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A;von Willebrand Diseases. MAH: CSL Behring GmbH. Decision date: 17/12/2024